Released Mar 29, 2019, after the close
10-K filed Apr 1, 2019, 91 days after period end · 0001564590-19-010253
Q4 2018 · 10-K
Revenue$19.09M$19.09M +372.4% vs Q4 2017+143.6% vs Q3 2018
Net Income-$1.49M-$1.49M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.07-$0.07 N/M vs Q4 2017N/M vs Q3 2018
Operating Incomederived-$3,275,000—
Operating Cash Flowderived-$5,935,000N/M
Free Cash Flowderived-$6,733,000N/M
Margins · derived
Operating margin-17.2%
Net margin-7.8%+372.0 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 |
|---|---|---|
| Revenue | $19.09M | $4.04M |
| Net Income | -$1.49M | -$15.34M |
| EPS Diluted | -$0.07 | -$33.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR